OrbiMed

Disc Medicine welcomes Dr. Mona Ashiya and Mark Chin to its Board along with raising $90m Series B financing led by OrbiMed

– USA, MA –  Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced a $90 million Series B financing led by OrbiMed alongside new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, and Alexandria Venture Investments.…

Q32 Bio adds Isaac Manke and Diyong Xu to Board along with raising $60m Series B financing co-led by OrbiMed Advisors and Acorn Bioventures

– USA, MA –  Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures, alongside Osage University Partners, Atlas Venture, Abingworth, Sanofi Ventures, CU Healthcare Innovation Fund and Children’s Hospital Colorado Center for Innovation also participating.…

Gracell Biotechnologies raises $100m Series C funding to fund research and development and advance clinical programs

– CHINA, Shanghai –  Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced it has secured $100 million in a Series C funding round led by Wellington Management Company, OrbiMed, and Morningside Ventures, and joined by new investor Vivo Capital.…

Talent4Boards
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.